ASSOCIATION BETWEEN MEDICATION USE AND BULLOUS PEMPHIGOID: A TEN-YEAR SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/r127hk31Keywords:
Medication, drugs, bullous pemphigoid, DIBPAbstract
Background: Bullous pemphigoid is an autoimmune subepithelial disease. It was associated with autoantibodies targeting hemidesmosome protein BPAG1 and BPAG2. The incidence of bullous pemphigoid has increased 1.9-4.3 times in the past two decades, possibly due to increased life expectancy, medication use, and improved diagnostic methods. Trigger factors of BP included drugs, physical factors, radiotherapy, trauma, and thermal exposure.
The aim: This study aims to determine association between medication use and bullous pemphigoid.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2014 and 2024 were taken into account. Several different online reference sources, like Pubmed and ScienceDirect, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Results: In the PubMed database, the results of our search brought up 1,662 articles, whereas the results of our search on ScienceDirect brought up 1,143 articles. The results of the search conducted by title screening yielded a total of 13 articles for PubMed and 32 articles for ScienceDirect. We compiled a total of 26 papers, 8 of which came from PubMed and 18 of which came from ScienceDirect. We excluded 2 review articles, 1 duplicate article, 3 non-full text articles, and 3 articles having insufficient outcomes. In the end, we included seventeen research that met the criteria.
Conclusion: Our study suggests that dipeptidyl peptidase-4 inhibitors and aldosterone antagonists are associated with BP. Other medications, such as immunomodulatory agents, anticonvulsants, tyrosine kinase inhibitors, antibiotics, anticoagulants, diuretics, and mRNA COVID-19 vaccine, may be associated with BP. Regarding these results, clinicians should pay close attention to prescribing the medicine to their patients.
References
Liu S De, Chen WT, Chi CC. Association between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis. JAMA Dermatol. 2020 Aug 1;156(8):891–900.
Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid. Vol. 94, Anais brasileiros de dermatologia. NLM (Medline); 2019. p. 133–46.
Zhang J, Wang G. Genetic predisposition to bullous pemphigoid. Vol. 100, Journal of Dermatological Science. Elsevier Ireland Ltd; 2020. p. 86–91.
Schaffer C, Buclin T, Jornayvaz FR, Cazzaniga S, Borradori L, Gilliet M, et al. Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid. Vol. 233, Dermatology. S. Karger AG; 2018. p. 401–3.
Baigrie D, Nookala V. Bullous Pemphigoid. In: StatPearls Publishing [Internet]. 2023 [cited 2024 Feb 19]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535374/
Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G. Bullous pemphigoid: Trigger and predisposing factors. Vol. 10, Biomolecules. MDPI AG; 2020. p. 1–29.
Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-associated bullous pemphigoid. Vol. 100, Acta Dermato-Venereologica. Medical Journals/Acta D-V; 2020. p. 1–9.
Alshammari F, Abuzied Y, Korairi A, Alajlan M, Alzomia M, AlSheef M. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report. Annals of Medicine and Surgery. 2022 Mar 1;75.
Arslan D, Aksakal AB, Erdem Ö, Tuncer MA. A case of drug-induced bullous pemphigoid associated with teriflunomide: A patient with relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Aug 1;43.
Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2018 Jun 1;78(6):1090–6.
Flamm A, Sachdev S, Dufresne F. Gabapentin-induced bullous pemphigoid. Journal of the American Osteopathic Association. 2017 Mar 1;117(3):191–3.
Le Guern A, Alkeraye S, Vermersch-Langlin A, Coupe P, Vonarx M. Bullous pemphigoid during ustekinumab therapy. JAAD Case Rep. 2015;1(6):359–60.
Guo JY, Chen HH, Yang YC, Wu PY, Chang MP, Chen CC. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study. J Diabetes Complications. 2020 Mar 1;34(3).
Hasson AM, Cheeney G, Ho LA, Vary JC. Bullous pemphigoid associated with nintedanib. JAAD Case Rep. 2019 Sep 1;5(9):821–3.
Iguchi N, Minabe M, Akira Y, Inada J, Akiyama Y, Hashimoto K, et al. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid with oral mucosal lesions: A case report. J Oral Maxillofac Surg Med Pathol. 2023 Nov 1;35(6):559–63.
Kridin K, Bergman R. Association of Bullous Pemphigoid with Dipeptidyl-Peptidase 4 Inhibitors in Patients with Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients. JAMA Dermatol. 2018 Oct 1;154(10):1152–8.
Liang J (Calvin), Raman K, Chan SH, Tashakkor AY. Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation. CJC Open. 2021 Oct 1;3(10):1316–9.
Qiu C, Shevchenko A, Hsu S. Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis. JAAD Case Rep. 2020 May 1;6(5):400–2.
Sanchez II, Yale K, Lee BA. A case of bullous pemphigoid provoked by doxycycline-induced phototoxicity. JAAD Case Rep. 2023 Jul 1;37:41–4.
Santaliz-Ruiz LEI, Blanco-Cintron ME, Caro-Muñiz AP, Villa J, Martin-Garcia RF. Levetiracetam-induced bullous pemphigoid in a young adult woman. JAAD Case Rep. 2022 Mar 1;21:56–8.
Sun CW, Grossman SK, Aphale A, Hsu S. Pembrolizumab-induced bullous pemphigoid. JAAD Case Rep. 2019 Apr 1;5(4):362–4.
Wu CY, Wu CY, Li CP, Chou YJ, Lin YH, Chang YT. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study. Diabetes Res Clin Pract. 2021 Jan 1;171.
Wurtz P, Borucki R, Georgesen C. A case of bullous pemphigoid induced by torsemide. JAAD Case Rep. 2022 Aug 1;26:95–7.
Yanai Y, Kori Y, Fujimoto T, Imajo I, Yanai R, Yamada T. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid diagnosed by oral manifestation. J Oral Maxillofac Surg Med Pathol. 2023 Nov 1;35(6):528–33.
Miao J, Gibson LE, Craici IM. Levofloxacin-Associated Bullous Pemphigoid in a Hemodialysis Patient After Kidney Transplant Failure. Am J Case Rep. 2022 Dec 29;23:e938476.
Kaul S, Wang A, Grushchak S, Albrecht J. Pembrolizumab-induced reactivation of bullous pemphigoid. Vol. 60, International Journal of Dermatology. Blackwell Publishing Ltd; 2021. p. 757–8.
Maronese CA, Caproni M, Moltrasio C, Genovese G, Vezzoli P, Sena P, et al. Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study. Front Med (Lausanne). 2022 Feb 28;9.
Wan V, Chen D, Shiau CJ, Jung GW. Association between COVID-19 vaccination and bullous pemphigoid – a case series and literature review. SAGE Open Med Case Rep. 2022;10.
Cozzani E, Chinazzo C, Burlando M, Romagnoli M, Parodi A. Ciprofloxacin as a Trigger for Bullous Pemphigoid: The Second Case in the Literature [Internet]. 2015. Available from: www.americantherapeutics.com
Helm MF, Lin L, Santalucia P, Brummitte ; 1, Wilson D, Plunkett ;, et al. Furosemide Induced Bullous Pemphigoid Associated with Antihistone Antibodies. N Am J Med Sci (Boston). 2014;7(2):84–6.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
